MiR-24 induces chemotherapy resistance and hypoxic advantage in breast cancer. 2017

Giuseppina Roscigno, and Ilaria Puoti, and Immacolata Giordano, and Elvira Donnarumma, and Valentina Russo, and Alessandra Affinito, and Assunta Adamo, and Cristina Quintavalle, and Matilde Todaro, and Maria dM Vivanco, and Gerolama Condorelli
Department of Molecular Medicine and Medical Biotechnology, "Federico II" University of Naples, Naples, Italy.

Breast cancer remains one of the leading causes of cancer mortality among women. It has been proved that the onset of cancer depends on a very small pool of tumor cells with a phenotype similar to that of normal adult stem cells. Cancer stem cells (CSC) possess self-renewal and multilineage differentiation potential as well as a robust ability to sustain tumorigenesis. Evidence suggests that CSCs contribute to chemotherapy resistance and to survival under hypoxic conditions. Interestingly, hypoxia in turn regulates self-renewal in CSCs and these effects may be primarily mediated by hypoxic inducible factors (HIFs). Recently, microRNAs (miRNAs) have emerged as critical players in the maintenance of pluripotency and self-renewal in normal and cancer stem cells. Here, we demonstrate that miR-24 is upregulated in breast CSCs and that its overexpression increases the number of mammospheres and the expression of stem cell markers. MiR-24 also induces apoptosis resistance through the regulation of BimL expression. Moreover, we identify a new miR-24 target, FIH1, which promotes HIFα degradation: miR-24 increases under hypoxic conditions, causing downregulation of FIH1 and upregulation of HIF1α. In conclusion, miR-24 hampers chemotherapy-induced apoptosis in breast CSCs and increases cell resistance to hypoxic conditions through an FIH1-HIFα pathway.

UI MeSH Term Description Entries
D012097 Repressor Proteins Proteins which maintain the transcriptional quiescence of specific GENES or OPERONS. Classical repressor proteins are DNA-binding proteins that are normally bound to the OPERATOR REGION of an operon, or the ENHANCER SEQUENCES of a gene until a signal occurs that causes their release. Repressor Molecules,Transcriptional Silencing Factors,Proteins, Repressor,Silencing Factors, Transcriptional
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002465 Cell Movement The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell. Cell Migration,Locomotion, Cell,Migration, Cell,Motility, Cell,Movement, Cell,Cell Locomotion,Cell Motility,Cell Movements,Movements, Cell
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006899 Mixed Function Oxygenases Widely distributed enzymes that carry out oxidation-reduction reactions in which one atom of the oxygen molecule is incorporated into the organic substrate; the other oxygen atom is reduced and combined with hydrogen ions to form water. They are also known as monooxygenases or hydroxylases. These reactions require two substrates as reductants for each of the two oxygen atoms. There are different classes of monooxygenases depending on the type of hydrogen-providing cosubstrate (COENZYMES) required in the mixed-function oxidation. Hydroxylase,Hydroxylases,Mixed Function Oxidase,Mixed Function Oxygenase,Monooxygenase,Monooxygenases,Mixed Function Oxidases,Function Oxidase, Mixed,Function Oxygenase, Mixed,Oxidase, Mixed Function,Oxidases, Mixed Function,Oxygenase, Mixed Function,Oxygenases, Mixed Function
D000066673 Cell Self Renewal The ability of certain cell types, such as progenitor cells or tumor cells, to go through numerous cycles of CELL DIVISION while still maintaining an undifferentiated or partially differentiated state. Stem Cell Renewal,Stem Cell Self-Renewal,Cell Renewal, Stem,Cell Renewals, Stem,Cell Self Renewals,Cell Self-Renewal, Stem,Cell Self-Renewals, Stem,Renewal, Cell Self,Renewal, Stem Cell,Renewals, Cell Self,Renewals, Stem Cell,Self Renewal, Cell,Self Renewals, Cell,Self-Renewal, Stem Cell,Self-Renewals, Stem Cell,Stem Cell Renewals,Stem Cell Self Renewal,Stem Cell Self-Renewals
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured

Related Publications

Giuseppina Roscigno, and Ilaria Puoti, and Immacolata Giordano, and Elvira Donnarumma, and Valentina Russo, and Alessandra Affinito, and Assunta Adamo, and Cristina Quintavalle, and Matilde Todaro, and Maria dM Vivanco, and Gerolama Condorelli
February 2015, Journal of cellular physiology,
Giuseppina Roscigno, and Ilaria Puoti, and Immacolata Giordano, and Elvira Donnarumma, and Valentina Russo, and Alessandra Affinito, and Assunta Adamo, and Cristina Quintavalle, and Matilde Todaro, and Maria dM Vivanco, and Gerolama Condorelli
February 2018, Cancer biomarkers : section A of Disease markers,
Giuseppina Roscigno, and Ilaria Puoti, and Immacolata Giordano, and Elvira Donnarumma, and Valentina Russo, and Alessandra Affinito, and Assunta Adamo, and Cristina Quintavalle, and Matilde Todaro, and Maria dM Vivanco, and Gerolama Condorelli
August 2019, Journal of cellular biochemistry,
Giuseppina Roscigno, and Ilaria Puoti, and Immacolata Giordano, and Elvira Donnarumma, and Valentina Russo, and Alessandra Affinito, and Assunta Adamo, and Cristina Quintavalle, and Matilde Todaro, and Maria dM Vivanco, and Gerolama Condorelli
November 2016, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
Giuseppina Roscigno, and Ilaria Puoti, and Immacolata Giordano, and Elvira Donnarumma, and Valentina Russo, and Alessandra Affinito, and Assunta Adamo, and Cristina Quintavalle, and Matilde Todaro, and Maria dM Vivanco, and Gerolama Condorelli
January 1998, Anticancer research,
Giuseppina Roscigno, and Ilaria Puoti, and Immacolata Giordano, and Elvira Donnarumma, and Valentina Russo, and Alessandra Affinito, and Assunta Adamo, and Cristina Quintavalle, and Matilde Todaro, and Maria dM Vivanco, and Gerolama Condorelli
January 2019, OncoTargets and therapy,
Giuseppina Roscigno, and Ilaria Puoti, and Immacolata Giordano, and Elvira Donnarumma, and Valentina Russo, and Alessandra Affinito, and Assunta Adamo, and Cristina Quintavalle, and Matilde Todaro, and Maria dM Vivanco, and Gerolama Condorelli
April 2013, The Journal of biological chemistry,
Giuseppina Roscigno, and Ilaria Puoti, and Immacolata Giordano, and Elvira Donnarumma, and Valentina Russo, and Alessandra Affinito, and Assunta Adamo, and Cristina Quintavalle, and Matilde Todaro, and Maria dM Vivanco, and Gerolama Condorelli
March 2023, International journal of molecular sciences,
Giuseppina Roscigno, and Ilaria Puoti, and Immacolata Giordano, and Elvira Donnarumma, and Valentina Russo, and Alessandra Affinito, and Assunta Adamo, and Cristina Quintavalle, and Matilde Todaro, and Maria dM Vivanco, and Gerolama Condorelli
December 2021, Cancers,
Giuseppina Roscigno, and Ilaria Puoti, and Immacolata Giordano, and Elvira Donnarumma, and Valentina Russo, and Alessandra Affinito, and Assunta Adamo, and Cristina Quintavalle, and Matilde Todaro, and Maria dM Vivanco, and Gerolama Condorelli
January 2013, PloS one,
Copied contents to your clipboard!